Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market (By Vector Type: AAV, Lentivirus; By Workflow; By Application; By End-use; By Disease) - Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2024-2033

Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market Size and Growth

The Asia Pacific viral vector and plasmid DNA manufacturing market was estimated at USD 1.03 billion in 2023 and it is expected to surpass around USD 7.48 billion by 2033, poised to grow at a CAGR of 21.93% from 2024 to 2033. The Asia Pacific region is witnessing significant growth in the viral vector and plasmid DNA manufacturing market, driven by advancements in biotechnology and gene therapy research.

Key Pointers

• The China viral vector and plasmid DNA manufacturing market held a revenue share of 20% in 2023
• By Vector Type, the adeno-associated virus (AAV) segment held the largest revenue share of 21% in 2023.
• By Vector Type, the lentivirus segment is estimated to expand the fastest CAGR of 22.03% from 2024 to 2033.
• By Workflow, the downstream processing segment contributed the largest market share of 54% in 2023.
• By Application, the vaccinology segment generated the maximum market share of 23% in 2023.
• By End-use, the research institutes captured the maximum market share of 58% in 2023.
• By Disease, the cancer segment had the largest market share of 39% in 2023.

Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market Growth Factors

The growth of the Asia Pacific viral vector and plasmid DNA manufacturing market is driven by an increasing investment in biotechnology and gene therapy research across the region is fueling demand for viral vectors and plasmid DNA for gene delivery applications. Secondly, advancements in manufacturing technologies are enhancing production efficiency and scalability, enabling manufacturers to meet the growing demand for gene therapy products. Additionally, the rising prevalence of genetic disorders and chronic diseases in the Asia Pacific region underscores the need for innovative treatment solutions, further driving market growth. Moreover, favorable regulatory policies and initiatives aimed at promoting biopharmaceutical innovation are facilitating market expansion. Collaborations between academia, research institutions, and industry players are also fostering innovation and driving market growth by facilitating knowledge exchange and technology transfer.

Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market Trends:

• Adoption of Advanced Manufacturing Technologies: The Asia Pacific viral vector and plasmid DNA manufacturing industry are witnessing a trend towards the adoption of advanced manufacturing technologies such as single-use systems, continuous processing, and automation to improve efficiency, scalability, and reduce production costs.
• Development of Novel Viral Vectors: There is a growing focus on the development of novel viral vectors with enhanced safety profiles, tissue specificity, and transduction efficiency. This trend is driven by the need for more effective gene therapy treatments and the exploration of new therapeutic targets.
• Expansion of Contract Development and Manufacturing Organizations (CDMOs): The region is experiencing a rise in the number of Contract Development and Manufacturing Organizations (CDMOs) specializing in viral vector and plasmid DNA manufacturing. This trend reflects the increasing demand for outsourced manufacturing services and expertise in gene therapy development.
• Emergence of Gene Editing Technologies: Advances in gene editing technologies such as CRISPR-Cas9 are reshaping the landscape of gene therapy research and development in the Asia Pacific region. These technologies offer precise and targeted gene editing capabilities, opening up new possibilities for the treatment of genetic diseases.
• Focus on Scalable and Cost-Effective Manufacturing Solutions: With the growing demand for viral vectors and plasmid DNA for gene therapy applications, there is a trend towards the development of scalable and cost-effective manufacturing solutions. Companies are exploring innovative approaches to streamline production processes and reduce manufacturing costs while maintaining product quality and compliance with regulatory standards.

Vector Type Insights

The adeno-associated virus (AAV) segment dominated the market in 2023, capturing the largest revenue share at 21%. AAV is increasingly favored for its precise gene delivery capabilities, driving its adoption across various research applications in gene therapy. Moreover, AAV-based vectors are gaining traction in neuroscience research, serving as a valuable preclinical tool for brain connectivity mapping and studying neurocircuit and cellular functions.

Meanwhile, the lentivirus segment is forecasted to exhibit the highest compound annual growth rate (CAGR) of 22.03% during the projected period. Lentiviral vectors have demonstrated notable success in reprogramming induced pluripotent stem cells (iPSCs) and have been instrumental in utilizing a Cre-Lox-based reversible system, opening new avenues for research. This development has paved the way for therapeutic exploration in iPSC technology.

Workflow Insights

The downstream processing segment led the market in 2023, commanding a revenue share of 54%. This segment encompasses various purification methods involving multiple steps, typically categorized into capture, intermediate purification, and polishing stages.

Conversely, the upstream processing segment is poised for a robust growth trajectory, with a projected CAGR of 21.03% during the forecast period. Upstream processing involves the initial steps of introducing cells to the virus, cultivating these cells, and isolating the virus from them. Innovations in product development, such as the ambr 15 microbioreactor system for high-throughput upstream process development, are expected to propel advancements in this field.

Application Insights

In 2023, the vaccinology segment commanded the largest revenue share of 23%, driven by the escalating demand for vaccines to combat infectious diseases. Ongoing research on various viral vectors underscores their potential in accelerating the development of viral vector-based vaccines.

Concurrently, the cell therapy segment is anticipated to grow at a notable CAGR of 24.23% over the forecast period. The adoption of next-generation transfer vectors has facilitated the increasing utilization of cell therapy-based medicines, with patient samples expanded, extracted, and transduced using gene therapy vectors.

End-use Insights

Research institutes dominated the market in 2023, capturing a revenue share of 58%. The segment's growth is fueled by the rising demand for viral vectors and the growing involvement of scientific communities in gene and cell therapy research. Research entities' efforts to enhance vector production techniques are further propelling segment growth.

Meanwhile, pharmaceutical and biotechnology companies are expected to witness a CAGR of 22.24% over the forecast period. Increased investments in cell and gene therapy have prompted many biopharmaceutical companies to shift focus, resulting in heightened research activities to explore the potential of these advanced therapies.

Disease Insights

The cancer segment emerged as the dominant revenue contributor in 2023, capturing a share of 39%. This growth trajectory is fueled by the escalating incidence of cancer cases and the extensive use of plasmid DNA and viral vectors in developing gene therapies. Lifestyle factors, including Western dietary habits and sedentary lifestyles, are also contributing to the rising prevalence of cancer.

The genetic disorders segment is poised for significant growth, with a projected CAGR of 22.03% during the forecast period. Gene therapy has emerged as a promising treatment modality for rare genetic disorders such as hemophilia, Adenosine Deaminase-Severe Combined Immunodeficiency (ADA-SCID), and Lipoprotein Lipase Deficiency (LPLD). These conditions stem from genetic abnormalities or missing genes, affecting specific traits. While most genetic disorders manifest from birth, some may arise due to spontaneous mutations. Common genetic diseases encompass sickle cell anemia and hemophilia, characterized by abnormal hemoglobin production and impaired blood clotting, thereby affecting oxygen transport in the blood.

Country Insights

The China viral vector and plasmid DNA manufacturing market held a revenue share of 20% in 2023, driven by advancements in the regulatory framework governing cell-based research activities within the country. Additionally, numerous biopharmaceutical companies are redirecting their focus toward advanced therapies, fueling investments in cell and gene therapy. Notably, VectorBuilder's announcement of a USD 500 million investment in April 2022 to establish a state-of-the-art cell and gene therapy research and manufacturing facility in Guangzhou, China, underscores this trend. Equipped to produce various forms of vectors, including AAV, plasmids, cell lines, lentivirus, and mRNA, this facility is anticipated to catalyze the growth of the viral vector and plasmid DNA manufacturing market in China.

The Japan viral vector and plasmid DNA manufacturing market are projected to grow at a CAGR of 20.63% over the forecast period, driven by its well-developed pharmaceutical and biotechnology sectors within the region. Moreover, the high prevalence of chronic diseases and rare genetic disorders has spurred intensified research and development efforts aimed at novel therapies and vaccines. Consequently, there is a heightened demand for plasmid DNA manufacturing solutions for research purposes in Japan.

Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market Key Companies

• FUJIFILM Holdings Corporation
• Wuxi Biologics
• Takara Bio Inc.
• Astellas Pharma, Inc. (Audentes Therapeutics)
• Lonza
• Charles River Laboratories (Cobra Biologics)
• Virovek Incorporation
• BioMarin

Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market Segmentation:

By Vector Type

• Adenovirus
• Retrovirus
• Adeno-Associated Virus (AAV)
• Lentivirus
• Plasmids
• Others

By Workflow

• Upstream Manufacturing
• Vector Amplification & Expansion
• Vector Recovery/Harvesting
• Downstream Manufacturing
• Purification
• Fill Finish

By Application

• Antisense & RNAi Therapy
• Gene Therapy
• Cell Therapy
• Vaccinology
• Research Applications

By End-use

• Pharmaceutical and Biopharmaceutical Companies
• Research Institutes

By Disease

• Cancer
• Genetic Disorders
• Infectious Diseases
• Others

By Country

• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand